Abstract |
The influence of experimental rhinitis on the absorption of buserelin, measured as the serum luteinizing hormone (LH) response, has been investigated. A single dose of 200 micrograms buserelin was given to 24 healthy male volunteers after induction of experimental rhinitis with histamine and after use of a saline spray (placebo control). Except on one occasion, when the pump-spray apparently was incorrectly operated, serum LH concentration rose after buserelin. There was no difference in the LH response between histamine-induced rhinitis and saline controls. It was concluded that intranasal application of buserelin represents a reliable mode of application and that modification of the administration route or a change in the dosage schedule during naturally-occurring nasal inflammations, such as the common cold and allergic rhinitis, is unnecessary in patients undergoing chronic treatment with intranasal buserelin, e.g. for prostatic cancer, endometriosis, precocious puberty, and contraception.
|
Authors | C Larsen, M Niebuhr Jørgensen, B Tommerup, N Mygind, E E Dagrosa, H G Grigoleit, V Malerczyk |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 33
Issue 2
Pg. 155-9
( 1987)
ISSN: 0031-6970 [Print] Germany |
PMID | 3121354
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Histamine
- Luteinizing Hormone
- Buserelin
|
Topics |
- Absorption
- Administration, Intranasal
- Adult
- Airway Resistance
(drug effects)
- Biological Availability
- Buserelin
(administration & dosage, adverse effects, pharmacology)
- Female
- Histamine
(pharmacology)
- Humans
- Luteinizing Hormone
(blood)
- Male
- Random Allocation
- Rhinitis
(metabolism)
|